THERAPY DOSSIER · th-005d84029ead

Transdermal optogenetic inhibition of CGRPalpha sensory neurons via archaerhodopsin-3; separately, peripheral blockade of CGRPalpha peptide-receptor signalling

Other

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29925650 ↗2018Mixed findings

Optogenetic Inhibition of CGRPalpha Sensory Neurons Reveals Their Distinct Roles in Neuropathic and Incisional Pain.

MouseOtherTransgenic mice selectively expressing archaerhodopsin-3 (Arch) in CGRPalpha neuronsMale and femaleTransdermal light activation for optogenetic inhibition; peripheral (local) administration for receptor blockadeApplied after injury, assessed longitudinally from acute to chronic time points

Model: Skin-muscle incision (inflammatory or incisional pain) and spared nerve injury (neuropathic pain)

After spared nerve injury, brief Arch activation reversed chronic mechanical, cold and heat hypersensitivity, alleviated spontaneous pain and reversed sensitised mechanical currents in afferent somata. Arch inhibition did not alter incision-induced hypersensitivity; instead, incision-induced mechan…

Extraction: extract · Supplied extraction confidence: 0.68. Machine-extracted fields require source verification.

Loading the evidence…